^
    1d
    Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment (clinicaltrials.gov)
    P2, N=15, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended
    Trial suspension • Circulating tumor DNA
    |
    Signatera™
    |
    AMB-05X
    1d
    Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Northside Hospital, Inc.
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 deletion
    |
    Venclexta (venetoclax) • decitabine • Niktimvo (axatilimab-csfr)
    6d
    STARS-RC10: Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria (clinicaltrials.gov)
    P2/3, N=212, Recruiting, The First Hospital of Jilin University
    New P2/3 trial
    |
    Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin • Sulanda (surufatinib)
    8d
    Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
    New P2 trial
    |
    pimicotinib (ABSK021)
    11d
    SNDX-6352-0506: MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov)
    P2, N=145, Active, not recruiting, Syndax Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Niktimvo (axatilimab-csfr)
    11d
    Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1/2, N=160, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Vonjo (pacritinib)
    13d
    A Monotherapy in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, 3D Medicines (Beijing) Co., Ltd. | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    segigratinib (3D185)
    18d
    MOTION: Study of Vimseltinib for Tenosynovial Giant Cell Tumor (clinicaltrials.gov)
    P3, N=123, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Trial completion date: Jul 2026 --> Jul 2028
    Trial completion date
    |
    Romvimza (vimseltinib)
    20d
    Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, Chipscreen Biosciences, Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Feb 2026 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • Auraza (chiauranib)
    22d
    AGAVE-201: A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (clinicaltrials.gov)
    P2, N=241, Active, not recruiting, Syndax Pharmaceuticals | Trial completion date: Dec 2027 --> Sep 2027
    Trial completion date
    |
    CSF1 (Colony stimulating factor 1)
    |
    Niktimvo (axatilimab-csfr)
    25d
    OSU-23442: Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Uma Borate | Trial completion date: Dec 2026 --> Oct 2028 | Trial primary completion date: Dec 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    SF3B1 (Splicing Factor 3b Subunit 1)
    |
    SF3B1 mutation
    |
    azacitidine • Niktimvo (axatilimab-csfr)
    25d
    Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • oxaliplatin • irinotecan • Sulanda (surufatinib)